Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 1/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.48 |
| ▸ | JAK2 | O60674 | 1/20 | 0.48 |
| ▸ | JAK1 | P23458 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | TACR1 | P25103 | 1/20 | 0.46 |
| ▸ | STS | P08842 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.44 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | PTPRB | P23467 | 1/20 | 0.43 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8649196 | 0.92 | OPRD1 (0.45) | OPRD1OPRK1JAK2JAK1TSHR | |
| SCHEMBL12492182 | 0.90 | OPRD1 (0.43) | OPRD1OPRK1JAK2JAK1TSHR | |
| SCHEMBL5520738 | 0.89 | JAK2 (0.50) | OPRD1OPRK1JAK2JAK1TSHR | |
| SCHEMBL12493077 | 0.89 | ATM (0.45) | OPRD1OPRK1JAK2JAK1TSHR | |
| SCHEMBL16827186 | 0.88 | TACR1 (0.48) | OPRD1OPRK1JAK2JAK1TSHR | |
| SCHEMBL13277303 | 0.85 | OPRD1 (0.45) | OPRD1OPRK1JAK2JAK1TSHR | |
| SCHEMBL12492823 | 0.85 | OPRD1 (0.46) | OPRD1OPRK1JAK2JAK1TSHR | |
| SCHEMBL2951728 | 0.84 | OPRD1 (0.53) | OPRD1OPRK1TSHRALOX15TACR1 | |
| SCHEMBL28049009 | 0.82 | AVPR1A (0.43) | OPRD1OPRK1 | |
| SCHEMBL27313194 | 0.82 | OPRD1 (0.47) | OPRD1OPRK1JAK2JAK1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3265459-B1 | AMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | SUVEN LIFE SCIENCES LTD (IN) | 2019-05-15 | — | — | EP | disclosed |
| CN-105873920-B | As 5-HT4The indazole compound of receptor stimulating agent | 苏文生命科学有限公司 | 2018-06-08 | — | — | CN | disclosed |
| EP-2976337-B1 | 5-AMINO-QUINOLINE-8-CARBOXAMIDE DERIVATIVES AS 5-HT4 RECEPTOR AGONISTS | SUVEN LIFE SCIENCES LTD (IN) | 2018-05-02 | — | — | EP | disclosed |
| EP-2976337-B1 | 5-AMINO-QUINOLINE-8-CARBOXAMIDE DERIVATIVES AS 5-HT4 RECEPTOR AGONISTS | SUVEN LIFE SCIENCES LTD (IN) | 2018-05-02 | — | — | EP | disclosed |
| US-9957257-B2 | Amide compounds as 5-HT4 receptor agonists | SUVEN LIFE SCIENCES LIMITED (IN) | 2018-05-01 | — | — | US | disclosed |
| US-9957257-B2 | Amide compounds as 5-HT4 receptor agonists | SUVEN LIFE SCIENCES LIMITED (IN) | 2018-05-01 | — | — | US | disclosed |
| US-9957257-B2 | Amide compounds as 5-HT4 receptor agonists | SUVEN LIFE SCIENCES LIMITED (IN) | 2018-05-01 | — | — | US | disclosed |
| US-9951045-B2 | Indazole compounds as 5-HT4 receptor agonists | SUVEN LIFE SCIENCES LIMITED (IN) | 2018-04-24 | — | — | US | disclosed |
| US-9951045-B2 | Indazole compounds as 5-HT4 receptor agonists | SUVEN LIFE SCIENCES LIMITED (IN) | 2018-04-24 | — | — | US | disclosed |
| US-9951045-B2 | Indazole compounds as 5-HT4 receptor agonists | SUVEN LIFE SCIENCES LIMITED (IN) | 2018-04-24 | — | — | US | disclosed |
| US-20160280694-A1 | 5-AMINO-QUINOLINE-8-CARBOXAMIDE DERIVATIVES AS 5-HT4 RECEPTOR AGONISTS | SUVEN LIFE SCIENCES LIMITED (IN) | 2016-09-29 | — | — | US | disclosed |
| US-20160280694-A1 | 5-AMINO-QUINOLINE-8-CARBOXAMIDE DERIVATIVES AS 5-HT4 RECEPTOR AGONISTS | SUVEN LIFE SCIENCES LIMITED (IN) | 2016-09-29 | — | — | US | disclosed |
| WO-2016128990-A1 | AMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | SUVEN LIFE SCIENCES LIMITED (IN) | 2016-08-18 | — | — | WO | disclosed |
| WO-2016128990-A1 | AMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | SUVEN LIFE SCIENCES LIMITED (IN) | 2016-08-18 | — | — | WO | disclosed |
| CN-105873920-A | Indazole compounds as 5-HT4 receptor agonists | 苏文生命科学有限公司 | 2016-08-17 | — | — | CN | disclosed |
| EP-2976337-A1 | 5-AMINO-QUINOLINE-8-CARBOXAMIDE DERIVATIVES AS 5-HT4 RECEPTOR AGONISTS | Suven Life Sciences Limited (IN) | 2016-01-27 | — | — | EP | disclosed |
| CN-105164119-A | 5-amino-quinoline-8-carboxamide derivatives as 5-ht4 receptor agonists | SUVEN LIFE SCIENCES LTD | 2015-12-16 | — | — | CN | disclosed |
| WO-2015092804-A1 | INDAZOLE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | SUVEN LIFE SCIENCES LIMITED (IN) | 2015-06-25 | — | — | WO | disclosed |
| WO-2015092804-A1 | INDAZOLE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | SUVEN LIFE SCIENCES LIMITED (IN) | 2015-06-25 | — | — | WO | disclosed |
| WO-2014147636-A1 | 5-AMINO-QUINOLINE-8-CARBOXAMIDE DERIVATIVES AS 5-HT4 RECEPTOR AGONISTS | SUVEN LIFE SCIENCES LIMITED (IN) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160280694-A1 | 5-AMINO-QUINOLINE-8-CARBOXAMIDE DERIVATIVES AS 5-HT4 RECEPTOR AGONISTS | HTR4, HTR5A, HTR1A | OPRD1 88/4885OPRK1 67/4885JAK2 1624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.